邮寄粪便免疫化学检测与全科医生处领取的成本效益比较
法国结直肠癌筛查参与率低于欧洲指南可接受的45%,可能与需在全科医生处领取粪便免疫化学检测(FIT)有关。研究采用微模拟模型模拟2018年法国35岁及以上人群,比较现行筛查方案与将FIT邮寄给参与者且依从性假设提高至45%的方案。结果显示邮寄FIT若使参与率升至45%,可减少6%的结直肠癌死亡和3%的结直肠癌病例,每获得一个质量调整生命年(QALY)的成本效益比为2149欧元。
要点
- 邮寄FIT使参与率升至45%可减少6%结直肠癌死亡和3%病例。
- 该干预的成本效益比为每QALY 2149欧元。
- 参与率仅需提高0.7个百分点即具成本效益。
核心结论
- 将FIT纳入邀请信邮寄可能是提高结直肠癌筛查参与率且极具成本效益的干预措施。
研究设计与样本
- 采用成熟的微模拟模型模拟2018年法国35岁及以上人群,比较现行筛查方案与邮寄FIT且依从性提高至45%的方案。
主要发现
- 现行方案下每1000人一生中预计发生53.8例结直肠癌和25.2例结直肠癌死亡。
- 邮寄FIT使参与率升至45%可减少6%的结直肠癌死亡和3%的结直肠癌病例。
- 该干预的成本效益比为每QALY 2149欧元。
- 邮寄FIT仅需使参与率提高0.7个百分点即被认为具有成本效益。
关键数值与推荐
- 欧洲指南认为可接受的结直肠癌筛查参与率为45%。
- 邮寄FIT使参与率升至45%时,成本效益比为每QALY 2149欧元。
- 成本效益阈值对应的参与率提高幅度为0.7个百分点。
临床怎么用
- 可考虑将FIT随邀请信邮寄以提高结直肠癌筛查参与率。
- 对于需在药房或全科医生处领取FIT的国家,该结果具有参考价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Participation in the colorectal cancer screening programme in France has been well below the 45% considered acceptable by European guidelines, potentially attributable to the need to collect the faecal immunochemical test (FIT) at the general practitioner. AIM: To estimate the potential benefits and costs of including the FIT in the invitation letter. METHODS: A well-established microsimulation model was used to simulate the French population 35 years and older in 2018. We estimated quality-adjusted life-years (QALY) gained, costs and cost-effectiveness of the current screening programme, and compared it to a variation of the programme where the FIT was mailed to participants and adherence was assumed to increase to 45%. We also estimated the threshold increase in participation needed to make this intervention cost-effective. RESULTS: Under the current programme, 53.8 colorectal cancer (CRC) cases and 25.2 CRC deaths per 1000 individuals are expected to occur over a lifetime. If sending out the FIT increases screening participation to 45%, this intervention would result in 6% fewer CRC deaths and 3% fewer CRC cases, resulting in an estimated cost-effectiveness ratio of €2149 per QALY gained. Sending out the FIT would only need to increase participation by 0.7% point for this intervention to be considered cost-effective. CONCLUSION: Including the FIT in the invitation letter is likely a very cost-effective intervention to increase participation in CRC screening. These results for France are also informative for many other countries around the world where FIT needs to be collected at pharmacies or general practitioners.
引用
- Peterse EFP, Osoro CB, Bardou M, et al. Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner. Aliment Pharmacol Ther. 2021. PMID: 33684238. doi:10.1111/apt.16317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。